4161.TWO Bioptik Technology
- Market cap
- TWD 1.24B
- P/E
- 11.2x
- P/B
- 1.23x
- ROE
- 11.4%
- Dividend yield
- 1.28%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4161.TWO undervalued?
Graham number4161.TWO trades 21.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bioptik Technology fundamental analysis
No fundamental analysis for Bioptik Technology yet.
Bioptik Technology stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bioptik Technology
Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. The company offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch, a glucose monitoring system for dogs and cats. It also provides dietary supplements, such as capsules, gel capsules, tablets, solutions,…
Full company profileBioptik Technology financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bioptik Technology annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 476M | 520M | 566M | 486M | 738M | 768M | 829M | 865M | 837M | 924M |
| Gross Profit | 115M | 126M | 149M | 83.2M | 164M | 177M | 240M | 268M | 244M | 258M |
| Operating Income | 4.95M | 726K | 467K | -56.8M | 27.1M | 71.8M | 118M | 90.0M | 66.5M | 72.5M |
| EBITDA | -567K | 73.9M | 50.6M | -19.0M | 64.1M | 105M | 152M | 155M | 126M | 171M |
| Net Income | -33.7M | 26.4M | 5.25M | -60.0M | 22.6M | 48.5M | 85.7M | 93.6M | 71.2M | 112M |
| EPS | -0.66 | 0.55 | 0.11 | -1.18 | 0.45 | 0.95 | 1.67 | 1.56 | 1.19 | 1.88 |
| Balance Sheet | ||||||||||
| Total Assets | 1.57B | 1.60B | 1.55B | 1.47B | 1.52B | 1.52B | 1.50B | 1.49B | 1.57B | 1.62B |
| Total Liabilities | 678M | 792M | 786M | 738M | 829M | 797M | 674M | 582M | 597M | 630M |
| Shareholders' Equity | 878M | 804M | 763M | 730M | 690M | 715M | 819M | 901M | 969M | 988M |
| Cash & Short-term Investments | 398M | 258M | 445M | 410M | 345M | 333M | 394M | 381M | 399M | 410M |
| Total Debt | - | - | - | 641M | 686M | 663M | 523M | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 11.0M | 41.8M | 41.0M | 6.57M | -41.2M | 55.1M | 206M | 159M | 60.0M | 39.9M |
| Capital Expenditure | 62.7M | 51.0M | 27.4M | 13.2M | 19.8M | 17.1M | 31.0M | 15.5M | 22.8M | 14.9M |
| Free Cash Flow | -52.0M | -10.1M | 12.5M | -6.61M | -61.0M | 38.0M | 175M | 143M | 37.2M | 25.0M |
| Ratios | ||||||||||
| ROE | -3.8% | 3.3% | 0.7% | -8.2% | 3.3% | 6.8% | 10.5% | 10.4% | 7.3% | 11.4% |
| ROA | -2.2% | 1.6% | 0.3% | -4.1% | 1.5% | 3.2% | 5.7% | 6.3% | 4.5% | 6.9% |
| Net Profit Margin | -7.1% | 5.1% | 0.9% | -12.4% | 3.1% | 6.3% | 10.3% | 10.8% | 8.5% | 12.1% |
| Debt to Equity | - | - | - | 0.88x | 0.99x | 0.93x | 0.64x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Bioptik Technology dividends
- Dividend yield
- 1.28%
- Forward dividend
- 0.70 TWD
- Payout ratio
- 22.3%
- Ex-dividend date
- Jul 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 15.9M | 0.27 | 22.3% |
| 2024 | TWD 37.1M | 0.62 | 39.6% |
| 2023 | - | - | - |
| 2022 | TWD 14.5M | 0.28 | 29.9% |
| 2021 | TWD 14.5M | 0.29 | 64.1% |
| 2020 | TWD 29.0M | 0.57 | - |
| 2019 | TWD 24.1M | 0.50 | 459.6% |
| 2018 | TWD 24.1M | 0.50 | 91.5% |
| 2017 | TWD 50.2M | 0.98 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1130.0369:1000 on Aug 20, 2025.
Who owns Bioptik Technology
- Insiders 28.32%
- Institutions 0.00%
- Public & others 71.68%
- Shares outstanding 59.8M
- Free float 41.2M
Bioptik Technology company profile
- Company name
- Bioptik Technology
- Ticker
- 4161.TWO
- ISIN
- TW0004161005
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Fiscal year end
- December
- Address
- No. 188, Jhonghua South Road, Zhunan, Taiwan, 35057
- Phone
- 886 3 762 6699
- Website
- bioptik.com.tw
About Bioptik Technology
Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. The company offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch, a glucose monitoring system for dogs and cats. It also provides dietary supplements, such as capsules, gel capsules, tablets, solutions, powder sachet, jelly, and gummy; cosmetic products, including sunscreen, cream/lotion, make-up removal, shampoo, time capsule, and toner/essence; and skin care products. In addition, the company is involved in manufacturing feed, canned food, and food additive, aircraft and parts, and chemicals; wholesale and import and export trade of cosmetics raw materials, semi-finished products and finished products; cosmetics retail and wholesale; and special forestry management. Bioptik Technology Incorporation was founded in 1999 and is based in Zhunan, Taiwan.
Bioptik Technology management
4- Mr. Jin-Chang YangGM & Chairman of the Board
- Mr. Yao-Jen TuChief Executive Officer
- Qiaoyun XuFinance Division Manager & Accounting Supervisor
- Mr. Kun Lie WuExecutive Officer